Cognition Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US19243B1026
USD
1.76
0.15 (9.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

940.05 k

Shareholding (Jun 2025)

FII

1.00%

Held by 6 FIIs

DII

80.15%

Held by 6 DIIs

Promoter

14.44%

How big is Cognition Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Cognition Therapeutics, Inc. has a market capitalization of 17.36 million, with net sales of 0.00 million and a net profit of -33.30 million over the last four quarters. The company reported shareholder's funds of 18.75 million and total assets of 30.23 million as of Dec 24.

Market Cap: As of Jun 18, Cognition Therapeutics, Inc. has a market capitalization of 17.36 million, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Cognition Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -33.30 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 18.75 million and total assets of 30.23 million.

Read More

What does Cognition Therapeutics, Inc. do?

22-Jun-2025

Cognition Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $8 million and a market cap of $17.36 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.32.

Overview: <BR>Cognition Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 17.36 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.32 <BR>Return on Equity: -271.39% <BR>Price to Book: 1.41<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Cognition Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Cognition Therapeutics, Inc. shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, despite mixed signals from KST and Dow Theory, while significantly outperforming the S&P 500 year-to-date and over the past year, but underperforming over the last three years.

As of 8 September 2025, the technical trend for Cognition Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands also reflect a mildly bullish stance on both weekly and monthly time frames. However, the KST shows a bullish weekly signal but a bearish monthly signal, and the Dow Theory indicates a mildly bearish weekly trend with no trend monthly. The moving averages are mildly bullish on a daily basis. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 109.61% compared to the S&P 500's 12.22%, and over the past year, it has returned 145.37% versus the S&P 500's 17.14%. However, it has underperformed over the last three years with a return of -16.0% compared to the S&P 500's 70.41%. Overall, the current technical stance is mildly bullish, driven by the positive signals from MACD and Bollinger Bands, despite some bearish indicators from KST and Dow Theory.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 212 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.61

stock-summary
Return on Equity

-469.38%

stock-summary
Price to Book

30.12

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-25.74%
0%
-25.74%
6 Months
467.93%
0%
467.93%
1 Year
354.9%
0%
354.9%
2 Years
46.67%
0%
46.67%
3 Years
-37.37%
0%
-37.37%
4 Years
-78.82%
0%
-78.82%
5 Years
0%
0%
0.0%

Cognition Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-189.87%
EBIT to Interest (avg)
-39.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.32
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
47.01%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.49
EV to EBIT
-0.04
EV to EBITDA
-0.04
EV to Capital Employed
-0.52
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-271.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (4.41%)

Foreign Institutions

Held by 6 Foreign Institutions (1.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 4.29% vs -48.94% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.90",
          "val2": "-14.60",
          "chgp": "4.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.70",
          "val2": "-7.00",
          "chgp": "4.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -31.78% vs -20.56% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.70",
          "val2": "-50.50",
          "chgp": "-6.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.00",
          "val2": "-25.80",
          "chgp": "-31.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-13.90
-14.60
4.79%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.70
-7.00
4.29%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 4.29% vs -48.94% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-53.70
-50.50
-6.34%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-34.00
-25.80
-31.78%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -31.78% vs -20.56% in Dec 2023

stock-summaryCompany CV
About Cognition Therapeutics, Inc. stock-summary
stock-summary
Cognition Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available